Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...

Rocket Pharmaceuticals, Inc.'s innovative therapies show promise after FDA setbacks. With potential $1B+ markets, RCKT offers ...

Washington — Senator Kirsten Gillibrand announced new legislation that would, as she says, make prescription drugs more ...

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

And if so, what is Trump’s plan to lower, not raise drug prices?” said a statement from Brown. Trump’s action ended federal testing of three new models to lower drug costs. One of them ...

SaveHealth explores the potential savings that can be achieved by intelligently leveraging cash prices and discount savings cards, providing insights based on real-world drug pricing data.

Seven cardiometabolic medications incur the most Medicare Part D spending among drugs up for price negotiation. The majority of spending on these drugs occurs with the first decade of U.S. market ...